Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
14
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-10-13 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding bamiquibalt (1-year data in macular edema associated with non-infectious uveitis).”
09
Oct
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-10-08 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (259.9KB) regarding the approval of Enhertu® for postoperative drug therapy for HER2-positive early breast cancer in China will open in a new window.”
09
Oct
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-10-08 DAIICHI SANKYO COMPANY,LIMITED “The announcement regarding the approval of Datroway® for triple-negative breast cancer in China (284.7KB) will open in a new window as a PDF file.”
09
Oct
Astellas Pharma Inc. JP3942400007
2026-10-08 Astellas Pharma Inc. “Selected as the No. 1 company in the pharmaceutical sector of the "Excellent Disclosure Companies" awards, organized by the Securities Analysts Association of Japan.”
08
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-07 Shionogi & Co.,Ltd. “Regarding the results of the activities in the Republic of Kenya and the Republic of Ghana during the third phase of the "Mother to Mother SHIONOGI Project".”
08
Oct
Astellas Pharma Inc. JP3942400007
2026-10-07 Astellas Pharma Inc. “We will present data on our oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) in 2026.”
08
Oct
Kyowa Kirin Co.,Ltd. JP3256000005
2026-10-07 Kyowa Kirin Co.,Ltd. “BridgeBio announces acceptance of its U.S. FDA application and priority review designation for infigratinib, an oral medication for pediatric patients with achondroplasia (671KB).”
07
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-06 Shionogi & Co.,Ltd. “Regarding the transfer of manufacturing and marketing authorization and sales of the desensitization therapy drug "Acitea® Dust Mite Sublingual Tablets".”
06
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-05 Shionogi & Co.,Ltd. “Announcement regarding investment in Cereido Therapeutics Co., Ltd. through CVC.”
06
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-05 Shionogi & Co.,Ltd. “Announcement Regarding the Wholly Owned Acquisition of IntraBio, Inc. (USA)”
03
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-02 Otsuka Holdings Co.,Ltd. “The American Medical Association (AMA) CPT Editorial Panel has approved the creation of two new Category I CPT codes related to renal denervation (link to Recor English page).”
03
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-02 Otsuka Holdings Co.,Ltd. “A joint research and development project on next-generation cancer immunotherapy utilizing quantum computing technology, involving NEC, Taiho Pharmaceutical, the Cancer Institute, AIST, and Waseda University, has been selected for a NEDO demonstration project.”
03
Oct
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-10-02 DAIICHI SANKYO COMPANY,LIMITED “A PDF file (231.9KB) announcing our partnership with Summit Therapeutics regarding combination therapy with datopotamab deruxtecan (Dato-DXd/DS-1062) will open in a new window.”
03
Oct
Eisai Co.,Ltd. JP3160400002
2026-10-02 Eisai Co.,Ltd. “Notice regarding receipt of dividends from a consolidated subsidiary.”
03
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-02 Sumitomo Pharma Co.,Ltd. “Regenerative medicine aimed at restoring function in patients with "pituitary insufficiency."”
03
Oct
Kyowa Kirin Co.,Ltd. JP3256000005
2026-10-02 Kyowa Kirin Co.,Ltd. “The "XLH Café," which connects patients living with XLH, will be held for the fifth consecutive year (698KB).”
02
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-01 Otsuka Holdings Co.,Ltd. “Taiho Pharmaceutical and Taiho Oncology have published the results of the Phase III AZTOUND trial of an oral azacitidine-cedazuridine combination drug for myelodysplastic syndrome or chronic myelomonocytic leukemia.”
01
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-30 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement regarding the establishment of a subsidiary in South Korea.”
01
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-09-30 Shionogi & Co.,Ltd. “Information regarding funding provided to medical institutions, etc. (for fiscal year 2025) has been released.”
01
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-09-30 Shionogi & Co.,Ltd. “Information regarding funding provided to patient organizations (for fiscal year 2025) has been released.”